Article

Modified steroid has 'potential' for treating subfoveal CNV in AMD

Author(s):

Fort Lauderdale, FL-Anecortave acetate (Alcon), a chemically modified steroid, acts in a unique way to suppress abnormal blood vessel growth in patients with subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.